(August 26, 2015) Women with epithelial ovarian cancer who happened to be taking nonselective beta-blockers for hypertension survived longer than those who were not taking the drugs, according to a … Continued
(August 21, 2015) A study published online in JAMA Oncology this month shows that screening women with a suspected risk of hereditary breast or ovarian cancer with a multigene panel … Continued
(August 19, 2015) Deleterious mutations in RAD51C and RAD51D genes are associated with increased risk of epithelial ovarian cancer (EOC), according to a study published online Aug. 10 in the … Continued
(August 19, 2015) Whereas chemotherapy kills cancer cells only while it is being administered, immunotherapy can lead to an adaptive immune response that persists long after treatment is ceased. By … Continued
(August 17, 2015) A study from the University of California, Davis found that one-third of women with ovarian cancer survive at least 10 years after diagnosis. The study, published in … Continued
(August 4, 2015) A study published online in the Journal of Clinical Oncology reports that although the use of intraperitoneal chemotherapy (IP)/IV chemotherapy increased significantly at major cancer centers between … Continued
(July 30, 2015) Recurrent ovarian cancer patients have more hope today, thanks to OCRF-funded research by David Pepin, PhD at Massachusetts General Hospital. Dr. Pepin and his colleagues found that … Continued
(July 29, 2015) Research published online in the Journal of Clinical Oncology shows that upon completion of primary therapy, women with low-grade serous carcinoma of the ovary (LGSOC) or peritoneum … Continued
(July 23, 2015) New OCRF-funded research demonstrates that combining a PARP-inhibitor with immune therapy results in tumor rejection and long-term survival in a mouse model of BRCA1-deficient ovarian cancer. The … Continued
(July 21, 2015) A group of Chinese researchers compared clinical characteristics and prognosis between ovarian clear cell carcinoma (CCC) and serous carcinoma (SC), and found that women with ovarian CCC … Continued
(July 19, 2015) Ovarian cancer patients who are overweight or obese are often given less chemotherapy per pound of body weight in order to reduce the toxic side effects associated … Continued
(July 1, 2015) When bevacizumab was added to standard chemotherapy, ovarian cancer patients with a poor prognosis had an overall survival benefit, according to the ICON7 study published online this week … Continued
Get email updates about research news, action alerts, and ways to join the fight.
